

Substitute for form 1449A/PTO & 1449B/PTO			Complete if Known		
FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use as many sheets as necessary)</small>			Application Number	09/976,936	
			Filing Date	October 11, 2001	
			First Named Inventor	Eric MAYHEW et al.	
			Examiner Name	Gollamudi Kishore, Ph.D.	
Sheet	1	of	3	Attorney Docket Number	033388-371

U.S. PATENT DOCUMENTS				
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant or Cited Document	Issue/Publication Date (MM-DD-YYYY)
LH	3,752,886		MUNDER <i>et al.</i>	08-14-1973
	4,159,988		EIBL <i>et al.</i>	07-03-1979
	4,163,748		EIBL <i>et al.</i>	08-07-1979
	4,382,035		EIBL	05-03-1983
	4,734,225		EIBL	03-29-1988
	4,804,789		EIBL	02-14-1989
	4,920,016		ALLEN <i>et al.</i>	04-24-1990
	4,965,391		COUNSELL <i>et al.</i>	10-23-1990
	4,983,397		SCHROIT <i>et al.</i>	01-08-1991
	5,013,558		WOODLE <i>et al.</i>	05-07-1991
LH	5,436,234		EIBL	07-25-1995
	5,782,958		MAYHEW	06-09-1998

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation	
					Yes	No
LH	4132345		GERMANY	04-01-1993		
	4408011		GERMANY	11-02-1995		
JL	072294		JAPAN	07-1984		
	1583661		UNITED KINGDOM	01-28-1981		
	93/04673		WIPO	03-18-1993		
	93/08202		WIPO	04-29-1993		
	94/27580		WIPO	12-08-1994		

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
LH	BAZIL <i>et al.</i> , "Role of Endocytosis in the Action of Ether Lipids on WEHI-3B, HL60, and FEDCP-Mix A4 Cells", Cancer Res., 1990, 50: 7505, American Association for Cancer Research, Baltimore, Maryland	
	BERDEL, "Membrane-Interactive Lipids as Experimental Anti-Cancer Drugs", Br. J. Cancer, 1991, 64: 208, Nature Publishing Group, London, England	
	BERDEL, "Ether Lipids and Derivatives as Investigational Anticancer Drugs", Onkologie, 1990, 13: 245, Karger Publishers, Freiburg, Germany	
	BHATIA <i>et al.</i> , "Stereospecific Synthesis of Antitumor Active Thioether PAF Analogs", Lipids, 1991, 26(12): 1424, Baylor College of Medicine, Houston, Texas	
	BLUME <i>et al.</i> , "Specific Targeting with Poly(ethylene Glycol)-Modified Liposomes: Coupling of Homing Devices to the Ends of the Polymeric Chains Combines Effective Target Binding with Long Circulation Times", Biochim. Biophys. Acta., 1993, 1149: 180-184, Elsevier, Amsterdam, The Netherlands	
	DAICHO <i>et al.</i> , "Effects of Alkyl Glycosides Incorporated into Liposomes Prepared from Synthetic Amphiphiles on Their Tissue Distribution in Ehrlich Solid Tumor-Bearing Mice", BBA, 1992, 1107: 61, Elsevier, Amsterdam, The Netherlands	
	DARNELL <i>et al.</i> , "Molecular Cell Biology", 1986, pgs. 573-575, Scientific American Books, Inc., New York New York	
	DEAMER <i>et al.</i> , "Liposome Preparation: Methods and Mechanisms" in Liposomes (M. Ostro, editor), 1983, pgs. 27-52, Marcel Dekker, Inc., New York, New York	
Examiner Signature	<i>Kishore</i>	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
VA 56959.1

Substitute for form 1449USPTO & 1449USPTO			Complete if Known	
FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	09/976.936
			Filing Date	October 11, 2001
			First Named Inventor	Eric MAYHEW et al.
			Examiner Name	Gollamudi Kishore, Ph.D.
(Use as many sheets as necessary)			Attorney Docket Number	033388-371
Sheet	2	of	3	

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
lw	DIETZ-FELBINGER <i>et al.</i> , "Removal of Breast Cancer Cells from Bone Marrow by <i>In Vitro</i> Purging with Ether Lipids and Cryopreservation", <i>Cancer Res.</i> , 1993, 53: 3747, American Association for Cancer Research, Baltimore, Maryland
	DIVE <i>et al.</i> , "Multiparametric Flow Cytometry of the Modulation of Tumor Cell Membrane Permeability by Developmental Antitumor Ether Lipid SRI 62-834 in EMT6 Mouse Mammary Tumor and HL-60 Human Promyelocytic Leukemia Cells", <i>Cancer Res.</i> , 1991, 51: 799, American Association for Cancer Research, Baltimore, Maryland
	GABIZON <i>et al.</i> , "Prolongation of Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs", <i>Pharm. Res.</i> , 1993, 10(5): 703, Elsevier, Amsterdam, The Netherlands
	KAUFMANN-KOLLE <i>et al.</i> , "Liposomal Hexadecylphosphocholine (HEPC): <i>In Vitro</i> and <i>In Vivo</i> Application", <i>Chemical Abs.</i> 4: 10.09, Stanford University Libraries, Stanford, California
	LAYTON <i>et al.</i> , "The Interaction of Liposomes with Cells: The Relation of Cell Specific Toxicity to Lipid Composition", <i>Eur. J. Cancer</i> , 1980, 16: 64, Elsevier, Amsterdam, The Netherlands
	LEWIS <i>et al.</i> , "The Mesomorphic Phase Behavior of Lipid Bilayers", in <i>The Structure of Biological Membranes</i> (P. Yeagle, editor), 1992, pgs. 73-155 at pgs. 123-126, CRC Press, Inc., Boca Raton, Florida
	MUSCHLOL <i>et al.</i> , "Alkyl Phosphocholine: Toxicity and Anti-cancer Properties", <i>Lipids</i> , 1987, 22(11): 930, Baylor College of Medicine, Houston, Texas
	NAIRN, in "Remington's Pharmaceutical Science (A. Gennaro, editor), 1985, pgs. 1492-1517, Mack Publishing Co., Easton, Pennsylvania
	PARK <i>et al.</i> , "Some Negatively Charged Phospholipid Derivatives Prolong the Liposome Circulation <i>In Vivo</i> ", <i>Biochim. Biophys. Acta.</i> , 1992, 1108: 257, Elsevier, Amsterdam, The Netherlands
	POWIS <i>et al.</i> , "Selective Inhibition of Phosphatidylinositol Phospholipase C by Cytotoxic Ether Lipid Analogues", <i>Cancer Res.</i> , 1992, 52: 2835, American Association for Cancer Research, Baltimore, Maryland
	POWIS <i>et al.</i> , "The Cell Membrane and Cell Signals as Targets in Cancer Chemotherapy", <i>Cancer Res.</i> , 1990, 50: 2203, American Association for Cancer Research, Baltimore, Maryland
	REED <i>et al.</i> , "Antineoplastic Ether-Linked Phospholipid Induces Differentiation of Acute Myelogenous Leukemic KG-1 Cells into Macrophage-Like Cells", <i>Life Sci.</i> , 1991, 49: 1221, Pergamon Press, Oxford, England
	RUNGE <i>et al.</i> , "Destruction of Human Solid Tumors by Alkyl Lysophospholipids", <i>JNCI</i> , 1980, 64(6): 1301, Oxford University Press, Oxford, England
	TRITTON <i>et al.</i> , "How to Kill Cancer Cells: Membranes and Cell Signaling as Targets in Cancer Chemotherapy", <i>Cancer Cells</i> , 1990, 2(4): 95, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
	WORKMAN, "Antitumor Ether Lipids: Endocytosis as a Determinant of Cellular Sensitivity", <i>Cancer Cells</i> , 1991, 3(8): 315, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
	WORKMAN <i>et al.</i> , "Platelet-activating Factor (PAF) Antagonist WEB 2086 Does not Modulate the Cytotoxicity of PAF or Antitumor Alkyl Lysophospholipids ET-18-O-Methyl and SRIU 62-834 in HL-60 Promyelocytic Leukemia Cells", <i>Biochem. Pharmacol.</i> , 1991, 41(2): 319, Elsevier, Amsterdam, The Netherlands
	ZEISIG <i>et al.</i> , "Antineoplastic Activity <i>In Vitro</i> of Free and Liposomal Alkylphosphocholines", <i>Anti-Cancer Drugs</i> , 1993, 4: 57, Lippincott Williams & Wilkins, Amsterdam, The Netherlands
	KUCHERA <i>et al.</i> , "Novel Membrane-Interactive Ether Lipid Analogs that Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation", <i>AIDS Res. & Human Retroviruses</i> , 1990, 6(4): 491-501, Mary Ann Liebert, Inc., Publishers, New York, New York
gsk	BAKER <i>et al.</i> , "Inhibition of Chronic Relapsing Experimental Allergic Encephalomyelitis in the Mouse by the Alkyl-Lysophospholipid ET-18-O-CH ₃ ", <i>Int. J. Immunopharm.</i> , 1991, 13(4): 385-392, International Society for Immunopharmacology, Pergamon Press plc, Oxford, England

Examiner Signature	Kishore	Date Considered	2/04
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P., § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. VA 5696.1			

Subordinate for form 1449A/PTO & 1449B/PTO		Complete if Known	
FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(USE AS MUCH SPACE AS NECESSARY)</small>		Application Number	09/976,938
		Filing Date	October 11, 2001
		First Named Inventor	Eric MAYHEW et al.
		Examiner Name	Gollamudi Kishore, Ph.D.
		Attorney Docket Number	033388-371
Sheet	3	of	3

NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>lw</i>	MENDE, Chem Abstracts, 119(23): 205219 g, Stanford University Libraries, Stanford, California
<i>lw</i>	ZALIPSKY <i>et al.</i> , "Long Circulating, Cationic Liposomes Containing Amino-PEG-Phosphatidylethanolamine", FEBS Letters, 1994, 353: 71-74, Federation of European Biochemical Societies, Elsevier Science BV, Amsterdam, The Netherlands

Examiner Signature	<i>Concha</i>	Date Considered	2/04
-----------------------	---------------	--------------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
VA 56969.1